Your browser doesn't support javascript.
loading
Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment.
Sawada, Koji; Saitho, Yoshinori; Hayashi, Hidemi; Hasebe, Takumu; Nakajima, Shunsuke; Ikuta, Katsuya; Fujiya, Mikihiro; Okumura, Toshikatsu.
Affiliation
  • Sawada K; Department of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
  • Saitho Y; Department of Gastroenterology Asahikawa Kosei General Hospital Asahikawa Japan.
  • Hayashi H; Department of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
  • Hasebe T; Department of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
  • Nakajima S; Department of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
  • Ikuta K; Department of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
  • Fujiya M; Department of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
  • Okumura T; Department of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
JGH Open ; 3(4): 329-337, 2019 Aug.
Article in En | MEDLINE | ID: mdl-31406927

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: JGH Open Year: 2019 Document type: Article Country of publication: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: JGH Open Year: 2019 Document type: Article Country of publication: Australia